治疗向LRPPRC介导的OXPHOS合成用于癌症干预的治疗向
Yuxin Liang1,2, Lina Wang3, Ziyan Yang3
1Key Laboratory of Molecular Nanostructure and Nanotechnology, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.
向氨酸丰富的五蛋白重复含有 (LRPPRC) 蛋白质,对瘤生长至关重要,提供了选择性癌症治疗. 新的双作用化合物抑制LRPPRC的功能并触发其降解,有效地抑制瘤中的氧化酸化.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 氧化酸化 (OXPHOS) 助长瘤的进展和耐治疗性.
- 针对电子输送链 (ETC) 的传统OXPHOS抑制剂缺乏瘤选择性和有效性.
- 通过LRPPRC抑制线粒体基因表达提供了更强效和瘤选择性的策略.
研究的目的:
- 确定针对癌症治疗的LRPPRC的新型治疗策略.
- 为针对LRPPRC的小分子开发一个选平台.
- 在临床前癌症模型中评估新型LRPPRC抑制剂的疗效和安全性.
主要方法:
- 为LRPPRC开发一个小分子选平台.
- 识别抑制LRPPRCRNA结合并促进降解的双重功能化合物.
- 在各种癌症模型中对已识别的化合物的临床前评估.
主要成果:
- LRPPRC在癌症中过度表达,对恶性表型至关重要.
- LRPPRC稳定了线粒体mRNAs (mt-mRNAs) 并增强了它们的翻译.
- 双功能的化合物强烈抑制了OXPHOS,并在临床前模型中显示出有利的安全性.
结论:
- 准LRPPRC代表了癌症治疗的一个有希望的策略.
- 新型双作用化合物有效抑制LRPPRC功能并促进其降解.
- 进一步的开发需要共同晶体结构和增强的线粒体传递策略用于临床翻译.
更多相关视频
08:03Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
11:04An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
Published on: January 13, 2023
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
